발기부전 치료제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 투여 형태별, 지역별, 부문별 예측(2025-2030년)

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

발기부전 치료제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 발기부전 치료제 시장 규모는 2025년부터 2030년까지 연평균 9.13% 성장하여 2030년에는 49억 달러에 달할 것으로 예상됩니다.

발기부전 유병률의 증가는 시장 성장에 기여할 것으로 예상됩니다. 유럽 비뇨기과 학회에 따르면 2020년 40-70세 유럽 남성 인구의 발기부전 유병률은 약 52%인 것으로 나타났습니다. 또한, 보스턴대학교 의과대학에 따르면 40대 남성 인구의 약 22.0%, 70대 남성 인구의 약 49.0%가 발기부전을 앓고 있는 것으로 나타났습니다. 이처럼 노령 인구의 증가는 예측 기간 동안 발기부전 유병률을 증가시킬 것으로 예상되며, 이는 시장에 유리한 성장 기회를 창출할 것으로 예상됩니다.

엘라이 릴리는 릴리 환자 지원 프로그램(LPSP)을 통해 저렴한 가격으로 의약품을 제공함으로써 응급실 환자들을 돕고 있습니다. 이 프로그램은 캐나다 내 자격 요건을 갖춘 ED 보험 미가입 환자에게 경제적 지원을 제공하며, 이 프로그램에는 등록이 필요할 수 있습니다. 이처럼 시알리스 브랜드 버전에 이러한 지원 프로그램이 존재하면 저소득층 환자들의 구매를 용이하게 하고 매출 증가로 이어질 수 있습니다. 또한, 기업들은 해외 시장에서의 제품 제조 및 상업화를 위해 제휴 및 파트너십과 같은 이니셔티브를 취하고 있습니다. 예를 들어, 2022년 1월 페트로스 파마슈티컬스(Petros Pharmaceuticals Inc.)는 아바나필 정제의 상업적 생산을 위해 세계 위탁생산업체(CDMO)와 파트너십을 체결했습니다. 이 제휴는 기존 비바스와의 계약을 대신해 제품 공급을 지속하는 것을 목표로 하고 있습니다.

또한, 국립의학도서관(2021년)에 따르면, 중국 본토의 ED 환자를 대상으로 스텐드라의 안전성과 유효성을 평가하는 3상 임상시험이 사천해고제약유한공사에 의해 실시됐습니다. 임상시험 결과, 중국 ED 환자들에게 스텐드라 100mg과 200mg을 2회 투여한 결과, 개선된 효과를 확인했습니다. 이러한 임상적 유효성 입증은 Strenda(Avanafil)의 시장에서의 입지를 강화할 수 있을 것으로 보입니다. 그러나 발기부전에 대한 인식 부족, 치료에 대한 수치심, 위양성 이론, 질병에 대한 사회적 낙인, 신중함의 부족 등이 시장 성장을 저해할 수 있습니다. 유럽 비뇨기과 학회(EAU)가 실시한 조사에 따르면, 스페인인 중 18%만이 발기부전 치료에 대해 들어본 적이 있는 반면, 68.0%는 치료 효과를 믿는 것으로 나타났습니다.

발기부전 치료제 시장 보고서 하이라이트

• 제품별로는 비아그라 부문이 2024년 가장 큰 시장 점유율을 차지했는데, 이는 비아그라가 전 세계적으로 판매되고 있고 ED 환자들 사이에서 비아그라에 대한 인지도가 높아졌기 때문으로 분석됩니다.
• 북미가 2024년 발기부전 치료제 시장에서 50.54%의 매출 점유율을 차지하며 독주했습니다. 이는 이 지역의 높은 질병 부담, 강력한 의료 인프라, 치료용 신제품의 신속한 승인에 기인합니다.
• 2024년 경구 투여가 84.03%로 가장 큰 시장 점유율을 차지했습니다. 경구 투여는 편의성, 비침습성, 환자 선호도가 높기 때문에 경구 투여가 시장을 지배하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 발기부전 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 발기부전 치료제 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 발기부전 치료제 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 발기부전 치료제 시장 : 제품 변동 분석
• 발기부전 치료제 시장 : 제품별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• Viagra (sildenafil citrate)
• Cialis (Tadalafil)
• Stendra/Spedra (avanafil)
• Zydena (udenafil)
• 기타 약물

제5장 발기부전 치료제 시장 : 투여 방법 추정·동향 분석

• 부문 대시보드
• 발기부전 치료제 시장 : 투여 방법 변동 분석
• 발기부전 치료제 시장 : 투여 방법별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 경구 투여법
• 주사에 의한 투여 방법
• 기타 투여 방법

제6장 발기부전 치료제 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 시장 진출 기업 분류
• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업 시장 점유율 분석, 2024년
• 주요 기업 개요
  • Bayer AG
  • Lilly
  • GlaxoSmithKline PLC
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Lupin Limited
  • Futura Medical
  • Cure Pharmaceutical
  • 23andMe
  • Hims &Hers Health, Inc.
  • RO
  • BlueChew
  • GoodRx, Inc.

ksm

영문 목차

영문목차

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

• By product, the viagra segment held the largest market share in 2024 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
• North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 50.54% in 2024, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
• The oral mode segment accounted for the largest market share of 84.03% in 2024. The oral mode of administration is a dominant segment in the market, driven by its convenience, non-invasive nature, and widespread patient preference

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mode of Administration
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of erectile dysfunction
    • 3.2.1.2. Rising geriatric population
    • 3.2.1.3. Increasing research & development (R&D)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of healthcare infrastructure and manufacturing errors
    • 3.2.2.2. Lack of awareness about erectile dysfunction
• 3.3. Erectile Dysfunction Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Erectile Dysfunction Drugs Market: Product Movement Analysis
• 4.3. Erectile Dysfunction Drugs Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Viagra (sildenafil citrate)
  • 4.5.1. Viagra (sildenafil citrate) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Cialis (Tadalafil)
  • 4.6.1. Cialis (Tadalafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Stendra/Spedra (avanafil)
  • 4.7.1. Stendra/Spedra (avanafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Zydena (udenafil)
  • 4.8.1. Zydena (udenafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Other Drugs
  • 4.9.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Mode of Administration Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Erectile Dysfunction Drugs Market: Mode of Administration Movement Analysis
• 5.3. Erectile Dysfunction Drugs Market by Mode of Administration Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Oral Mode of Administration
  • 5.5.1. Oral Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Injectable Mode of Administration
  • 5.6.1. Injectable Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Other Modes of Administration
  • 5.7.1. Other Modes of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Key Company Profiles
  • 7.4.1. Bayer AG
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Lilly
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. GlaxoSmithKline PLC
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Petros Pharmaceuticals, Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Pfizer Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Teva Pharmaceutical Industries Ltd
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Lupin Limited
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Futura Medical
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Cure Pharmaceutical
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. 23andMe
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Hims & Hers Health, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. RO
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. BlueChew
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. GoodRx, Inc.
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives

관련자료